Institutes outside Greece
The role of Tis11 family in the pathophysiology of Chronic Lymphocytic Leukaemia
Abstract
dc:descriptionIn this study the basal expression of Tis11 family and their regulation in CLL (Chronic Lymphocytic Leukaemia) cells in response to stimuli that induce apoptosis (crosslinked Rituximab, XRituximab) or stimuli that inhibit spontaneous apoptosis (IL-4, CD40L, anti-CD40, antiCD40+IL-4, PMA) was tested. Members of the Tis11 family bind to AU Rich Elements (AREs) in the 3’ Untranslated Region (3’UTR) and induce degradation of mRNAs bearing these target sequences. The Tis11 family consists of Tis11 (or ZFP36), Tis11b (or ZFP36L1) and Tis11d (or ZFP36L2) which induce apoptosis when overexpressed in a variety of human cell lines (epithelial, osteosarcoma and fibroblasts). It was found that Tis11 mRNA is strongly expressed in unstimulated CLL cells, when compared to Tis11b mRNA levels, and was downregulated following stimulation with IL-4 or anti-CD40 at 3 hours post stimulation but remained unaffected by all other stimuli. Tis11b mRNA was found to be minimally expressed in unstimulated CLL cells and was strongly induced following Rituximab, XRituximab, PMA and anti-CD40 treatment in all patients tested but remained unchanged by IL-4 or anti-CD40+IL-4. Finally Tis11d was found to be strongly expressed in the vast majority of unstimulated CLL cells and was weakly induced by XRituximab and PMA in some but not all patients tested and showed no change after IL-4, anti-CD40 or antiCD40+IL-4 stimulation. Additionally it was found that when Tis11b is induced by XRituximab it is primarily regulated through p38 and to lesser extend through JNK pathway since inhibition of these pathways abrogated induction of the Tis11b mRNA and protein. On the contrary when Tis11b was induced by PMA or anti-CD40 it was found to be regulated through NF-κB pathway since inhibition of this pathway resulted in complete abrogation of Tis11b mRNA induction following PMA or anti-CD40 stimulation. In order to determine the function of Tis11b in reponse to XRituximab, PMA or anti-CD40 treatment, Tis11b siRNA technology was utilised which revealed that inhibition of Tis11b significantly reduced (by 50-70%) the efficiency ofXRituximab to induce apoptosis in CLL cells while when Tis11b siRNA was applied in PMA or anti-CD40 stimulated CLL cells it significantly reduced their ability to induce sIgM expression in these cells. Thus Tis11b is involved in induction of apoptosis following Rituximab treatment in CLL cells and also it is involved in differentiation of CLL cells when such a stimuli (eg: anti-CD40) are present. Finally it was found that Tis11b is probably involved in B cell differentiation in general, since it was found that it has different basal expression and regulation at different stages of B cell differentiation represented by Nalm6 (pre-B cells), Ramos and Daudi (Germinal Centre B cells), AGLCL and WILCL (memory B cells) and RPMI8226 and MM1.S (plasma cells) cell lines. Thus Tis11 family especially Tis11b and Tis11 may have an important role in the pathogenesis or progression of CLL (and possibly of other B cell malignancies) and necessitate further investigation.
Degree
thesis:*- Grantor dc:publisher
- Institutes outside Greece
- Year dc:date
- 2007
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Baou, Maria
- Μπάου, Μαρία
Subjects
dc:subject × 24- Απόπτωση
- Γενετική
- Β χρόνια λεμφοκυτταρική λευχαιμία
- Apoptosis
- MRNA degradation
- Chronic lymphocytic leukemia
- Rituximab
- In vitro B cell differentiation
- Άλλες Ιατρικές Επιστήμες
- Ιατρική και Επιστήμες Υγείας
- Ιατρική έρευνα και Πειραματική ιατρική
- Βιολογία
- Φυσικές Επιστήμες
- Βιολογία κυττάρου
- Γενετική και Κληρονομικότητα
- Βιοχημεία και Μοριακή βιολογία
- Other Medical Sciences
- Medical and Health Sciences
- Research and Experimental medicine
- Biological Sciences
- Natural Sciences
- Cell Biology
- Genetics and Heredity
- Biochemistry and Molecular Biology
Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/50285